Kymera Therapeutics, Inc. (KYMR)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Kymera Therapeutics, Inc. reported revenue of $39.21M, down 16.7% from the prior year. The company ran a net loss, with a net margin of -794.0%. It held $1.74B in total assets against $163.15M in total liabilities.
Key ratios (FY2025)
-891.1%
Operating margin
-794.0%
Net margin
-19.7%
Return on equity
-16.7%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $39.21M | $47.07M | $78.59M | $46.83M | $72.83M | $34.03M | $2.93M | — |
| Cost of Revenue | $39.21M | $47.07M | $78.59M | $46.83M | — | — | — | — |
| Operating Income | -$349.40M | -$261.63M | -$165.53M | -$161.26M | -$100.53M | -$46.30M | -$42.20M | — |
| Net Income | -$311.35M | -$223.86M | -$146.96M | -$154.81M | -$100.22M | -$45.59M | -$41.25M | — |
| EPS (Diluted) | $-3.69 | $-2.98 | $-2.52 | $-2.87 | $-2.09 | $-3.15 | — | — |
| Total Assets | $1.74B | $978.03M | $575.76M | $603.13M | $605.90M | $487.18M | $116.70M | — |
| Total Liabilities | $163.15M | $142.42M | $180.79M | $112.98M | $146.27M | $203.29M | $82.03M | — |
| Shareholders' Equity | $1.58B | $835.62M | $394.97M | $490.15M | $459.64M | $283.89M | -$74.41M | -$34.44M |
| Cash & Equivalents | $357.01M | $120.26M | $109.97M | $68.39M | $47.98M | $31.00M | $76.02M | — |
| Operating Cash Flow | -$232.89M | -$194.50M | -$102.83M | -$153.09M | -$128.95M | $88.13M | $17.91M | — |
| Capital Expenditures | $1.45M | $12.84M | $34.48M | $2.84M | $1.60M | $9.10M | $532.0K | — |
| Shares Outstanding | 81.32M | 64.89M | 55.59M | 55.04M | 51.54M | 44.48M | 1.93M | — |